Pacer Advisors
TVTX icon

Pacer Advisors’s Travere Therapeutics TVTX Stock Holding History

Pacer Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,037
Closed -$8.52K – 2699
2024
Q2 		$8.52K Sell
1,037
-1,734
-63% -$11.7K ﹤0.01% 3575
2024
Q1 		$21.4K Buy
+2,771
New +$23.4K ﹤0.01% 3431
2021
Q2 		– Sell
-2,293
Closed -$57K – 1556
2021
Q1 		$57K Buy
2,293
+744
+48% +$20.6K ﹤0.01% 1427
2020
Q4 		$42K Sell
1,549
-348
-18% -$8.13K ﹤0.01% 1433
2020
Q3 		$35K Buy
+1,897
New +$36.9K ﹤0.01% 1322
2018
Q4 		– Sell
-2,631
Closed -$76K – 1014
2018
Q3 		$76K Buy
+2,631
New +$75.2K ﹤0.01% 1117
2018
Q1 		– Sell
-650
Closed -$14K – 1131
2017
Q4 		$14K Buy
+650
New +$14.9K ﹤0.01% 1123

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pacer Advisors's TVTX Position: Q3 2024 in Review

Pacer Advisors sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 1,037 shares — an estimated $8.52K sold.

Pacer Advisors first reported a position in TVTX in Q4 2017 and held it in 7 quarters. The position peaked at $76K in Q3 2018. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

  • Pacer Advisors reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,037 Travere Therapeutics shares in Q3 2024, an estimated $8.52K.
  • Pacer Advisors first reported a position in Travere Therapeutics in Q4 2017 and held it in 7 quarters.
  • Pacer Advisors's Travere Therapeutics position peaked at $76K in Q3 2018.
  • 178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.